文献速递血栓与止血

黑色素瘤免疫、化疗或靶向治疗患者的血栓栓塞发生率、危险因素与结局

Incidence, risk factors, and outcomes of thromboembolism in patients with melanoma receiving immune checkpoint inhibitors, chemotherapy, or targeted therapy: a Surveillance, Epidemiology, and End Results-Medicare analysis.
PubMed 文献 · J Thromb Haemost · 2026-09-12

基于SEER-Medicare数据库2008至2019年6218例黑色素瘤患者,比较免疫检查点抑制剂、化疗或靶向治疗启动后2年内血栓栓塞发生率。各治疗类型静脉与动脉血栓栓塞累积发生率相近,血栓栓塞与生存期显著变差相关。

要点

  • 免疫、化疗或靶向治疗12个月静脉血栓栓塞累积发生率约7.4%–8.4%,动脉血栓栓塞约5.0%–6.5%。
  • 静脉血栓栓塞史和脑转移与静脉血栓栓塞风险升高相关,心血管病、糖尿病、动脉血栓栓塞史和抗血小板治疗与动脉血栓栓塞风险升高相关。
  • 静脉或动脉血栓栓塞患者生存期约差2倍,免疫亚组中伊匹木单抗/纳武利尤单抗联合静脉血栓栓塞风险高于纳武利尤单抗。

核心结论

  • 免疫检查点抑制剂、化疗和靶向治疗均与黑色素瘤患者高血栓栓塞发生率相关,且血栓栓塞与生存期显著变差相关。

研究设计与样本

  • 队列研究,使用SEER-Medicare数据库纳入2008至2019年接受免疫检查点抑制剂、化疗或BRAF/MEK抑制剂治疗的6218例黑色素瘤患者,评估治疗启动后2年内血栓栓塞发生率。

主要发现

  • 静脉血栓栓塞史(SHR 2.81,95%CI 2.19-3.61)和脑转移(SHR 1.33,95%CI 1.06-1.66)与静脉血栓栓塞风险升高相关。
  • 心血管病(SHR 1.49,95%CI 1.14-1.93)、糖尿病(SHR 1.27,95%CI 1.04-1.57)、动脉血栓栓塞史(SHR 1.61,95%CI 1.13-2.29)和抗血小板治疗(SHR 1.37,95%CI 1.03-1.83)与动脉血栓栓塞风险升高相关。
  • 静脉血栓栓塞(HR 2.17,95%CI 1.64-2.87)或动脉血栓栓塞(HR 2.58,95%CI 1.92-3.47)患者生存期约差2倍。

关键数值与推荐

  • 与纳武利尤单抗相比,伊匹木单抗/纳武利尤单抗联合(SHR 1.66,95%CI 1.09-2.54)和伊匹木单抗(SHR 1.43,95%CI 1.03-2.00)静脉血栓栓塞风险更高。
  • 免疫检查点抑制剂亚组中静脉血栓栓塞(HR 3.24,95%CI 2.30-4.58)和动脉血栓栓塞(HR 1.89,95%CI 1.20-2.99)与更差生存相关。

临床怎么用

  • 对接受免疫检查点抑制剂、化疗或靶向治疗的黑色素瘤患者,应关注血栓栓塞风险,尤其存在静脉血栓栓塞史、脑转移、心血管病、糖尿病、动脉血栓栓塞史或抗血小板治疗者。
  • 发生静脉或动脉血栓栓塞提示预后更差,需加强监测与综合管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about venous thromboembolism (VTE) and arterial thromboembolism (ATE) risk in melanoma patients receiving immune checkpoint inhibitors (ICIs) compared with other therapies. OBJECTIVES: We assessed the incidence, risk factors, and impact of thromboembolism (TE) on survival in patients receiving ICIs, chemotherapy, or targeted therapy. METHODS: We conducted a cohort study using the Surveillance, Epidemiology, and End Results-Medicare database to evaluate TE rates in patients treated with ICIs, chemotherapy, or BRAF/MEK inhibitors from 2008 to 2019, within 2 years after treatment initiation. Associations among TE, treatment, and clinical risk factors were evaluated using weighted competing risk regression. Overall survival was estimated by Kaplan-Meier and Cox regression models. RESULTS: Among 6218 patients, 62.1% (n = 3860) received first-line ICIs, 30.4% (n = 1890) received chemotherapy, and 7.5% (n = 468) received targeted therapy. The cumulative incidence of VTE was similar across all treatment types: 7.7% for ICIs, 8.4% for chemotherapy, and 7.4% for targeted therapy at 12 months (P = .80). Similarly, ATE rates were 5.3% for ICIs, 5.0% for chemotherapy, and 6.5% for targeted therapy at 12 months (P = .30). A history of VTE (subdistribution hazard ratio [SHR], 2.81 [95% CI, 2.19-3.61]) and brain metastases (SHR, 1.33 [95% CI, 1.06-1.66]) were associated with an increased risk of VTE. Compared with chemotherapy, ICIs and targeted therapy had a similar VTE risk (P > .05). For ATE, cardiovascular disease (SHR, 1.49 [95% CI, 1.14-1.93]), diabetes mellitus (SHR, 1.27 [95% CI, 1.04-1.57]), a history of ATE (SHR, 1.61 [95% CI, 1.13-2.29]), and antiplatelet therapy (SHR, 1.37 [95% CI, 1.03-1.83]) were associated with increased risk. Patients with VTE or ATE experienced a 2-fold worse survival (hazard ratio [HR], 2.17 [95% CI, 1.64-2.87] and HR, 2.58 [95% CI, 1.92-3.47], respectively). In the ICI subanalysis, the ipilimumab/nivolumab combination had a higher cumulative incidence of VTE: 11.9% at 12 months, 9.3% for ipilimumab, 7.5% for pembrolizumab, and 5.8% for nivolumab (P < .05). Compared with nivolumab, the ipilimumab/nivolumab combination (SHR, 1.66 [95% CI, 1.09-2.54]) and ipilimumab (SHR, 1.43 [95% CI, 1.03-2.00]) had a higher VTE risk. VTE and ATE were associated with worse survival (HR, 3.24 [95% CI, 2.30-4.58] and HR, 1.89 [95% CI, 1.20-2.99], respectively). CONCLUSION: ICIs, chemotherapy, and targeted therapy are associated with a high incidence of TE, and TE is associated with substantially worse survival.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Sussman TA, Vu L, Koroukian SM, et al. Incidence, risk factors, and outcomes of thromboembolism in patients with melanoma receiving immune checkpoint inhibitors, chemotherapy, or targeted therapy: a Surveillance, Epidemiology, and End Results-Medicare analysis. J Thromb Haemost. 2026. PMID: 42731732. doi:10.1016/j.jtha.2026.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。